Exenatide and pramlintide: New therapies for diabetes

International Journal of Clinical Practice

Volumn 60, Issue 12, 2006, Pages 1522-1523

  Want, L L ^a   Ratner, R ^b  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PRAMLINTIDE; SULFONYLUREA;

CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DRUG ACTIVITY; DRUG APPROVAL; DRUG INDICATION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; NAUSEA; NONHUMAN; OFF LABEL DRUG USE; PATIENT CARE; PRIORITY JOURNAL; UNITED STATES; VOMITING;

AMYLOID; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; VENOMS;

EID: 33750980387     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01219.x     Document Type: Editorial

References (11)

1. Ceriello A, Piconi L, Quagliaro L et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005, 28: 632-7.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
3. Edelman SV, Darsow T, Frias JP. Pramlintide in the treatment of diabetes. Int J Clin Pract 2006, 60: 1647-53.
4. [Symlin] Amylin Pharmaceuticals, Inc. 2005. Prescribing information [online]. http://www.symlin.com/pdf/SYMLIN-pi-combined.pdf (accessed September 2006).
5. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002; 20: 137-44.
6. Ratner RE, Whitehouse F, Fineman MS et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 2005; 113: 199-204.
7. Gallwitz B. Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 1654-61.
8. Poon T, Nelson P, Shen L et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study. Diabetes Technol Ther 2005; 7: 467-77.
9. [Byetta] Amylin Pharmaceuticals, Inc. 2006. Prescribing information [online]. http://pi.lilly.com/us/byetta-pi.pdf (accessed September 2006).
10. Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838-48.
11. Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-58.